PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignanciesYonghui Sun, Yu Rao, Yue Wu et al.|Cell Research|2018Cited by 280
Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomasYonghui Sun, Yu Rao, Ning Ding et al.|Leukemia|2019Cited by 144
Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in miceNing Ding|World Journal of Gastroenterology|2016Cited by 13